I have confidence that by the end of this year we will have data from the DFU trial. I have confidence that by the end of 2024 we will have data from the Renal trial. I have confidence that by mid-2025 we will have data from the GvHD trial.
The amalgamation of this data means that existing and prospective investors will have a much better understanding and trust in what Cynata can do. Therefore we will trade at a fairer price.
We could very-well fail all 3 trials, in which case we will be near $0. But it’s more likely that if at least 2 are successful, then institutional investors, and big pharma, will figure out that Cynata is worth a lot more than $0.32. In any case, we will trade at a fairer price.
CYP Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)